Lupin Gets US Regulator’s Nod For Hypertension Treatment Drug In US

New Delhi: Drug major Lupin has received a tentative approval from the US health regulator to sell Olmesartan Medoximil tablets, used for treating high blood pressure, in the American market.

“It has received tentative approval for Olmesartan medoximil tablets, 5 mg, 20 mg and 40 mg from the US Food and Drug Administration (USFDA),” Lupin Ltd said in a filing to the BSE on Monday.

Olmesartan Medoximil tablets, a generic version of Daiichi Sankyo’s Benicar, are indicated for the treatment of hypertension, along with other anti-hypertensive agents to lower blood pressure, it added.

Quoting IMS MAT September 2016 sales data, Lupin further said that Benicar tablets had annual US sales of $1.06 billion.

Shares in Lupin ended 2.78 per cent lower at Rs 1,405.10 apiece on the BSE, whose benchmark Sensex index finished down 0.90 per cent.